Aminah Jatoi

Aminah Jatoi

Auto-generated profile, based on publicly available information

Aminah Jatoi

Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2003 in Cancer
Verified
Journal Article
Open access
PDF file
AJAminah Jatoi
Aminah Jatoi
NENeil Ellison
Neil Ellison
PBPatrick A. Burch
Patrick A. Burch
JSJeff A. Sloan
Jeff A. Sloan
SDShaker R. Dakhil
Shaker R. Dakhil
PFPatrick J. Flynn
Patrick J. Flynn
BACKGROUND: Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma.METHODS: This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone‐releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long‐acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity.RESULTS: Tumor response, defined as a decline ≥ 50% in the baseline PSA value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1–14%). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity, usually Grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion.CONCLUSIONS: Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma. Cancer 2003;97:1442–6. © 2003 American Cancer Society.DOI 10.1002/cncr.11200

15 June 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AJAminah Jatoi
Aminah Jatoi
KRKendrith Rowland
Kendrith Rowland
CLCharles L. Loprinzi
Charles L. Loprinzi
JSJeff A. Sloan
Jeff A. Sloan
SDShaker R. Dakhil
Shaker R. Dakhil
BCBrad Christensen
Brad Christensen
Purpose: Studies suggest eicosapentaenoic acid (EPA), an omega-3 fatty acid, augments weight, appetite, and survival in cancer-associated wasting. This study determined whether an EPA supplement—administered alone or with megestrol acetate (MA)—was more effective than MA. Patients and Methods: Four hundred twenty-one assessable patients with cancer-associated wasting were randomly assigned to an EPA supplement 1.09 g administered bid plus placebo; MA liquid suspension 600 mg/d plus an isocaloric, isonitrogenous supplement administered twice a day; or both. Eligible patients reported a 5-lb, 2-month weight loss and/or intake of less than 20 calories/kg/d. Results: A smaller percentage taking the EPA supplement gained ≥ 10% of baseline weight compared with those taking MA: 6% v 18%, respectively (P = .004). Combination therapy resulted in weight gain of ≥ 10% in 11% of patients (P = .17 across all arms). The percentage of patients with appetite improvement (North Central Cancer Treatment Group Questionnaire) was not statistically different: 63%, 69%, and 66%, in EPA-, MA-, and combination-treated arms, respectively (P = .69). In contrast, 4-week Functional Assessment of Anorexia/Cachexia Therapy scores suggested MA-containing arms experienced superior appetite stimulation compared with the EPA arm, with scores of 40, 55, and 55 in EPA-, MA-, and combination-treated arms, respectively (P = .004). Survival was not significantly different among arms. Global quality of life was not significantly different among groups. With the exception of increased impotence in MA-treated patients, toxicity was comparable. Conclusion: This EPA supplement, either alone or in combination with MA, does not improve weight or appetite better than MA alone.

1 May 2010 in Lung Cancer
Verified
Journal Article
Closed access
AJAminah Jatoi
Aminah Jatoi
HRHoward L. Ritter
Howard L. Ritter
ADAmylou Dueck
Amylou Dueck
PNPhuong L. Nguyen
Phuong L. Nguyen
DNDaniel A. Nikcevich
Daniel A. Nikcevich
CLCharles L. Loprinzi
Charles L. Loprinzi

25 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
RDRichard Dunne
Richard Dunne
KLKah Poh Loh
Kah Poh Loh
GWGrant Williams
Grant Williams
AJAminah Jatoi
Aminah Jatoi
KMKaren M. Mustian
Karen M. Mustian
SMSupriya G. Mohile
Supriya G. Mohile
Cancer cachexia is a syndrome characterized by weight loss with accompanying loss of muscle and/or fat mass and leads to impaired patient function and physical performance and is associated with a poor prognosis. It is prevalent in older adults with cancer; age-associated physiologic muscle wasting and weakness, also known as sarcopenia, can compound deficits associated with cancer cachexia in older adults and makes studying this condition more complex in this population. Multiple measurement options are available to assess the older patient with cancer and cachexia and/or sarcopenia including anthropometric measures, imaging modalities such as Dual X-ray absorptiometry (DEXA) and Computed Tomography (CT), muscular strength and physical performance testing, and patient-reported outcomes (PROs). A geriatric assessment (GA) is a useful tool when studying the older patient with cachexia given its comprehensive ability to capture aging-sensitive PROs. Interventions focused on nutrition and increasing physical activity may improve outcomes in older adults with cachexia. Efforts to develop targeted pharmacologic therapies with cachexia have not been successful thus far. Formal treatment guidelines, an updated consensus definition for cancer cachexia and the development of a widely adapted assessment tool, much like the GA utilized in geriatric oncology, could help advance the field of cancer cachexia over the next decade.

9 June 2008 in Cancer
Verified
Journal Article
Open access
PDF file
AJAminah Jatoi
Aminah Jatoi
KRKendrith Rowland
Kendrith Rowland
JSJeff A. Sloan
Jeff A. Sloan
HGHoward M. Gross
Howard M. Gross
PFPaul A. Fishkin
Paul A. Fishkin
CLCharles L. Loprinzi
Charles L. Loprinzi
BACKGROUND.: Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention.METHODS.: This placebo‐controlled, double‐blinded trial enrolled patients who were starting cancer treatment with an EGFR inhibitor. Patients could not have had a rash at the time of enrollment. All patients were randomly assigned to receive either tetracycline at a dose of 500 mg orally twice a day for 28 days versus a placebo. Patients were monitored for rash (through monthly physician assessment and weekly patient‐reported questionnaires), quality of life (using the SKINDEX‐16, a skin‐specific quality of life index), and adverse events. Monitoring occurred during the 4‐week intervention and then for an additional 4 weeks. The primary objective of the current study was to compare the incidence of rash between the study arms, and the enrollment of 30 patients per arm provided a 90% probability of detecting a 40% difference in incidence with a P value of .05 (2‐sided).RESULTS.: A total of 61 evaluable patients were enrolled. The 2 treatment arms were well balanced with regard to baseline characteristics, dropout rates, and rates of discontinuation of the EGFR inhibitor. The incidence of rash was found to be comparable across treatment arms. Physicians reported that 16 patients treated with tetracycline (70%) and 22 patients treated with placebo (76%) developed a rash (P = .61). Tetracycline appears to have lessened the rash severity, although the high dropout rates invite caution when interpreting these findings. By Week 4, physician‐reported grade 2 rash (using the National Cancer Institute's Common Terminology Criteria for Adverse Events [version 3.0]) occurred in 17% of tetracycline‐treated patients (n = 4 patients) and in 55% of placebo‐exposed patients (n = 16 patients) (P = .04). Patients treated with tetracycline reported better scores, as per the SKINDEX‐16, on certain quality‐of‐life parameters such as skin burning or stinging, skin irritation, and being bothered by the persistence/recurrence of a skin condition. Adverse events were found to be comparable across treatment arms.CONCLUSIONS.: In the current study, tetracycline was not found to prevent EGFR inhibitor‐induced rashes and therefore cannot be clinically recommended for this purpose. However, preliminary observations of diminished rash severity and improved quality of life suggest this antibiotic merits further study. Cancer 2008. © 2008 American Cancer Society.

31 August 2007 in Cancer
Verified
Journal Article
Open access
PDF file
AJAminah Jatoi
Aminah Jatoi
SDShaker R. Dakhil
Shaker R. Dakhil
PNPhuong L. Nguyen
Phuong L. Nguyen
JSJeff A. Sloan
Jeff A. Sloan
JKJohn W. Kugler
John W. Kugler
CLCharles L. Loprinzi
Charles L. Loprinzi
BACKGROUND.: Tumor necrosis factor‐α (TNF‐α) is a putative mediator of the cancer anorexia/weight loss syndrome. The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand‐binding portion of the human 75‐kilodalton TNF receptor linked to the Fc portion of human immunoglobulin [Ig] G1) could palliate this syndrome.METHODS.: A total of 63 evaluable patients were randomly assigned to receive either etanercept at a dose of 25 mg subcutaneously twice weekly versus a comparably administered placebo. All patients had an incurable malignancy, acknowledged loss of weight and/or appetite as a concern, and reported a weight loss of >2.27 kg over 2 months and/or a daily intake of <20 calories/kg body weight.RESULTS.: Over time, weight gain was found to be minimal in both treatment arms; no patient gained ≥10% of their baseline weight. Previously validated appetite questionnaires revealed negligible improvements in both treatment arms. The median survival was also comparable (175 days vs 148 days in etanercept‐treated and placebo‐exposed patients, respectively; P = .82). Finally, preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%). Infection rates were negligible in both groups. Genotyping for TNF‐α‐238 and TNF‐α‐308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the −238 G/A genotype and relatively less favorable survival.CONCLUSIONS.: Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease. Cancer 2007. © 2007 American Cancer Society.